Pharma Company Achieves 4x Faster Target ID for Inflammatory Disease
Key Highlights
A pharmaceutical company based in Boston aimed to speed up their target discovery and validation process for inflammatory disease using single-cell RNA-seq data.
Elucidata systematically addressed this challenge by leveraging curated data on Polly and their expertise in analyzing single-cell RNA-seq data.
This resulted in the identification of four new targets and the validation of five pre-identified targets.
The pharma achieved a four-fold acceleration in target identification and validation with the help of this partnership.
.svg)
.svg)
%201%20(1).svg)
.svg)
%201.svg){kind=icon}
.svg)
%20(1).svg)
